The Potential Role of Erythropoietin in Chronic Heart Failure: From the Correction of Anemia to Improved Perfusion and Reduced Apoptosis?

Journal of Cardiac Failure

Volumn 15, Issue 4, 2009, Pages 353-361

  Timmer, Stefan A J ^a   De Boer, Karin ^a   Knaapen, Paul ^a   Götte, Marco J W ^a   Van Rossum, A C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anemia; apoptosis; neovascularization

Indexed keywords

DARBE POIETIN ALFA; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; IRON; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANEMIA; APOPTOSIS; BLOOD VISCOSITY; CHRONIC DISEASE; CLINICAL TRIAL; DRUG EFFECT; ELECTRIC POTENTIAL; ERYTHROPOIESIS; HEART FAILURE; HEART FUNCTION; HEART MUSCLE INJURY; HEART PERFUSION; HEART PROTECTION; HEMATOCRIT; HUMAN; IRON DEFICIENCY; LONG TERM CARE; LOW DRUG DOSE; MULTICENTER STUDY; NONHUMAN; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SAFETY; THROMBOEMBOLISM; VASCULAR CAPACITY; ANIMAL; DRUG EFFECTS; HEART MUSCLE REPERFUSION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

ANEMIA; ANIMALS; APOPTOSIS; CHRONIC DISEASE; ERYTHROPOIETIN; HEART FAILURE; HUMANS; MYOCARDIAL REPERFUSION;

EID: 65249088498     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2008.10.024     Document Type: Review

References (74)

1. Bleumink G.S., Knetsch A.M., Sturkenboom M.C., et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study. Eur Heart J 25 (2004) 1614-1619
2. Tang Y.D., and Katz S.D. The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes. Heart Fail Rev 13 (2008) 387-392
3. Lindenfeld J. Prevalence of anemia and effects on mortality in patients with heart failure. Am Heart J 149 (2005) 391-401
4. Felker G.M., Gattis W.A., Leimberger J.D., et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol 92 (2003) 625-628
5. Maggioni A.P., Opasich C., Anand I., et al. Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. J Card Fail 11 (2005) 91-98
6. Hamed S., Barshack I., Luboshits G., et al. Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur Heart J 27 (2006) 1876-1883
7. Hirata A., Minamino T., Asanuma H., et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol 48 (2006) 176-184
8. Li L., Takemura G., Li Y., et al. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 113 (2006) 535-543
9. Lipsic E., van der Meer P., Voors A.A., et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 20 (2006) 135-141
10. Lipsic E., Westenbrink B.D., van der Meer P., et al. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail. 10 (2008) 22-29
11. Prunier F., Pfister O., Hadri L., et al. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol 292 (2007) H522-H529
12. van der Meer P., Lipsic E., Henning R.H., et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 46 (2005) 125-133
13. Westenbrink B.D., Lipsic E., van der Meer P., et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 28 (2007) 2018-2027
14. Westenbrink B.D., Oeseburg H., Kleijn L., et al. Erythropoietin stimulates normal endothelial progenitor cell-mediated endothelial turnover, but attributes to neovascularization only in the presence of local ischemia. Cardiovasc Drugs Ther 22 (2008) 265-274
15. Burger D., Lei M., Geoghegan-Morphet N., et al. Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc Res 72 (2006) 51-59
16. Calvillo L., Latini R., Kajstura J., et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A 100 (2003) 4802-4806
17. Chong Z.Z., Kang J.Q., and Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 106 (2002) 2973-2979
18. Moon C., Krawczyk M., Ahn D., et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci U S A 100 (2003) 11612-11617
19. Parsa C.J., Matsumoto A., Kim J., et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112 (2003) 999-1007
20. Parsa C.J., Kim J., Riel R.U., et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem 279 (2004) 20655-20662
21. Tramontano A.F., Muniyappa R., Black A.D., et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 308 (2003) 990-994
22. Wojchowski D.M., Gregory R.C., Miller C.P., et al. Signal transduction in the erythropoietin receptor system. Exp Cell Res. 253 (1999) 143-156
23. Westenbrink B.D., de Boer R.A., Voors A.A., et al. Anemia in chronic heart failure: etiology and treatment options. Curr Opin Cardiol 23 (2008) 141-147
24. de Silva R., Rigby A.S., Witte K.K., et al. Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am J Cardiol 98 (2006) 391-398
25. Opasich C., Cazzola M., Scelsi L., et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 26 (2005) 2232-2237
26. Westenbrink B.D., Visser F.W., Voors A.A., et al. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J 28 (2007) 166-171
27. Iversen P.O., Woldbaek P.R., Tonnessen T., et al. Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol Regul Integr Comp Physiol 282 (2002) R166-R172
28. Weiss G., and Goodnough L.T. Anemia of chronic disease. N Engl J Med 352 (2005) 1011-1023
29. Silverberg D.S., Wexler D., Blum M., et al. The interaction between heart failure, renal failure and anemia-the cardio-renal anemia syndrome. Blood Purif 22 (2004) 277-284
30. Ezekowitz J.A., McAlister F.A., and Armstrong P.W. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12065 patients with new-onset heart failure. Circulation 107 (2003) 223-225
31. Nanas J.N., Matsouka C., Karageorgopoulos D., et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 48 (2006) 2485-2489
32. Ishani A., Weinhandl E., Zhao Z., et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 45 (2005) 391-399
33. Macdougall I.C. The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrol Dial Transplant 14 (1999) 1836-1841
34. Cody J., Daly C., Campbell M., et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev 3 (2005) CD003266
35. Sato T., Maekawa T., Watanabe S., et al. Erythroid progenitors differentiate and mature in response to endogenous erythropoietin. J Clin Invest 106 (2000) 263-270
36. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
37. Kourea K., Parissis J.T., Farmakis D., et al. Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil 15 (2008) 365-369
38. Mancini D.M., Katz S.D., Lang C.C., et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107 (2003) 294-299
39. Palazzuoli A., Silverberg D., Iovine F., et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 152 (2006) 1096.e9-15
40. Palazzuoli A., Silverberg D.S., Iovine F., et al. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 154 (2007) 645.e9-15
41. Ponikowski P., Anker S.D., Szachniewicz J., et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 49 (2007) 753-762
42. Silverberg D.S., Wexler D., Blum M., et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35 (2000) 1737-1744
43. Silverberg D.S., Wexler D., Sheps D., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37 (2001) 1775-1780
44. Silverberg D.S., Wexler D., Blum M., et al. Effects of treatment with epoetin beta on outcomes in patients with anaemia and chronic heart failure. Kidney Blood Press Res 28 (2005) 41-47
45. van Veldhuisen D.J., Dickstein K., Cohen-Solal A., et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 28 (2007) 2208-2216
46. Ghali J.K., Anand I.S., Abraham W.T., et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 117 (2008) 526-535
47. Mix T.C., Brenner R.M., Cooper M.E., et al. Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 149 (2005) 408-413
48. Depping R., Kawakami K., Ocker H., et al. Expression of the erythropoietin receptor in human heart. J Thorac Cardiovasc Surg 130 (2005) 877-878
49. Bahlmann F.H., de G.K., Spandau J.M., et al. Erythropoietin regulates endothelial progenitor cells. Blood 103 (2004) 921-926
50. Urbich C., and Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 95 (2004) 343-353
51. Watson T., Goon P.K., and Lip G.Y. Endothelial progenitor cells, endothelial dysfunction, inflammation, and oxidative stress in hypertension. Antioxid Redox Signal 10 (2008) 1079-1088
52. Werner N., Kosiol S., Schiegl T., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353 (2005) 999-1007
53. Zentilin L., Tafuro S., Zacchigna S., et al. Bone marrow mononuclear cells are recruited to the sites of VEGF-induced neovascularization but are not incorporated into the newly formed vessels. Blood 107 (2006) 3546-3554
54. Olson R.E. Myocardial metabolism in congestive heart failure. J Chronic Dis 9 (1959) 442-464
55. Stanley W.C., Recchia F.A., and Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85 (2005) 1093-1129
56. Ventura-Clapier R., Garnier A., and Veksler V. Energy metabolism in heart failure. J Physiol 555 (2004) 1-13
57. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med 356 (2007) 1140-1151
58. van den Heuvel A.F., van Veldhuisen D.J., van der Wall E.E., et al. Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 35 (2000) 19-28
59. Anversa P., Li P., Zhang X., et al. Ischaemic myocardial injury and ventricular remodelling. Cardiovasc Res 27 (1993) 145-157
60. de Boer R.A., Pinto Y.M., and van Veldhuisen D.J. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation 10 (2003) 113-126
61. Wright G.L., Hanlon P., Amin K., et al. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 18 (2004) 1031-1033
62. Clancy R.M., Leszczynska-Piziak J., and Abramson S.B. Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J Clin Invest 90 (1992) 1116-1121
63. Razavi H.M., Hamilton J.A., and Feng Q. Modulation of apoptosis by nitric oxide: implications in myocardial ischemia and heart failure. Pharmacol Ther 106 (2005) 147-162
64. Toma C., Letts D.P., Tanabe M., et al. Positive effect of darbepoetin on peri-infarction remodeling in a porcine model of myocardial ischemia-reperfusion. J Mol Cell Cardiol 43 (2007) 130-136
65. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
66. Henke M., Laszig R., Rübe C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
67. Leyland-Jones B., Semiglazov V., Pawlicki M., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23 (2005) 5960-5972
68. van der Lelie J. Concern about the safety of erythropoietin in cancer patients. Ned Tijdschr Geneeskd 152 (2008) 920-922
69. van Veldhuisen D.J., and McMurray J.J. Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. Eur J Heart Fail 9 (2007) 110-112
70. Leist M., Ghezzi P., Grasso G., et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305 (2004) 239-242
71. Fiordaliso F., Chimenti S., Staszewsky L., et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci U S A 102 (2005) 2046-2051
72. Moon C., Krawczyk M., Paik D., et al. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther 316 (2006) 999-1005
73. Bolger A.P., Bartlett F.R., Penston H.S., et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 48 (2006) 1225-1227
74. Toblli J.E., Lombrana A., Duarte P., et al. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50 (2007) 1657-1665